Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas

Moreno, Abelardo; Castilla-Guerra, Luis; Martı́nez-Torres, Martı́n; Torres-Olivera, F.; Fernández, Emilio; Galera-Davidson, H

doi:10.1054/npep.1999.0012

Cited by 31 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuron-specific enolase has also been advocated as a screening marker since it can be significantly elevated in patients with malignant phaeochromocytomas (Oishi & Sato 1988). Of the several other peptides that can be produced from chromaffin-cell tumours, adrenocorticotrophin over-expression has been related to malignancy (Moreno et al 1999).…”

Section: Biochemical Diagnosis Of Malignant Chromaffin-cell Tumoursmentioning

confidence: 99%

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Chrisoulidou

Kaltsas²,

Ilias³

et al. 2007

Endocr Relat Cancer

293

219

View full text Add to dashboard Cite

Malignant phaeochromocytomas are rare tumours accounting for w10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations. Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour. Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours. Although a number of recently introduced molecular markers have been explored, their clinical significance remains to be elucidated from further studies. Several imaging modalities have been utilised for the diagnosis and staging of these tumours. Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, 18 F-fluorodopamine and 18 F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies. The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion. Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using 131 I-MIBG; however, this is very rarely curative. Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect. The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving. Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.

show abstract

Section: Biochemical Diagnosis Of Malignant Chromaffin-cell Tumoursmentioning

confidence: 99%

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Chrisoulidou

Kaltsas²,

Ilias³

et al. 2007

Endocr Relat Cancer

293

219

View full text Add to dashboard Cite

show abstract

“…A subpopulation of sustentacular cells may be positive for glial fibrillary acidic protein (GFAP). A number of peptides produced by the normal medulla are also expressed in tumors [25], although these are not usually documented as part of the diagnostic procedure. The exception would be the confirmation of the tumor as the source of hormone secretion (e.g., adrenocorticotrophin, ACTH) in ectopic hormone syndromes [26].…”

Section: Immunohistochemistrymentioning

confidence: 99%

Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas

McNicol

2006

Endocr Pathol

View full text Add to dashboard Cite

Paragangliomas arise from sympathetic or parasympathetic paraganglia and should now be defined by their site and type. The term pheochromocytoma is reserved for intra-adrenal tumors. This short review discusses the gross and microscopic features, the immunohistochemical profile, the problem of recognizing malignant potential, and the rare instances where a differential diagnosis has to be considered.

show abstract

“…67 Hormones normally expressed in the adrenal medulla are usually not evaluated immunohistochemically, unlike ectopically produced hormones such as ACTH and corticotropin-releasing hormone in cases associated with a clinical syndrome. 68,69 Immunohistochemical markers are useful in differentiating pheochromocytomas from adrenal cortical tumors (Table 3).…”

Section: Adrenal Pheochromocytoma and Extraadrenal Paragangliomamentioning

confidence: 99%

Practical Markers Used in the Diagnosis of Endocrine Tumors

Erickson

Lloyd

2004

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Endocrine tumors constitute a large group of neoplasms that are widely dispersed throughout the body. They are made up mostly of neuroendocrine tumors (NE), which are characterized by the presence of secretory granules and production of peptide hormones, and non-NE tumors such as those derived from thyroid follicular cells and adrenal cortical cells. Immunohistochemical markers have been used to characterize these lesions and distinguish them from other histologically similar tumors. Chromogranin and synaptophysin are the most widely used broad-spectrum neuroendocrine tumor markers. The use of antibodies to transcription factors, keratins, and specific peptides is quite valuable in the diagnosis of endocrine tumors. This article reviews the common markers used to characterize endocrine tumors and to recognize tumors involved in the differential diagnosis of specific lesions.

show abstract

Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas

Cited by 31 publications

References 0 publications

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas

Practical Markers Used in the Diagnosis of Endocrine Tumors

Contact Info

Product

Resources

About